- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02286687
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine whether the PARP inhibitor talazoparib achieves clinical benefit (complete response [CR], partial response [PR] or stable disease [SD] > 24 weeks) in metastatic or inoperable locally advanced or locally recurrent cancer patients who have somatic mutations or deletions of BRCA1 or BRCA2, mutations or homozygous deletions in other BRCA pathway genes, and germline mutations in BRCA1 or BRCA 2 with cancers other than breast or ovarian cancer.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of talazoparib in this patient population. (Across-indication) II. To determine baseline molecular markers (deoxyribonucleic acid [DNA], ribonucleic acid [RNA] and protein) or scores (e.g., microsatellite instability positives, and somatic mutation burden) that may predict clinical benefit. (Within-indication) III. To determine pharmacodynamic (PD) markers in tumor, blood and plasma that may predict outcome. (Within-indication) IV. To determine concordance of BRCA1/2 alterations in archival tissue and pre-treatment biopsies. (Within-indication) V. To determine concordance of genomic alterations in tumor and circulating free DNA. (Within-indication) VI. To evaluate the progression free survival (PFS) in patients. (Within-indication) VII. To evaluate the duration of response (DOR) in patients. (Within-indication) VIII. To evaluate the overall survival (OR) in patients. (Within-indication)
OUTLINE:
Patients receive talazoparib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 12 weeks for 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with advanced or metastatic cancer that is refractory to standard therapy or has relapsed after standard therapy
- Patients must have one of the following: somatic mutations or deletions in BRCA1 or BRCA2; genomic alterations in other BRCA pathway genes (subcohorts: a. ATM, b. PALB2, c. other genes, e.g. Fanconi Anemia genes, ARID1A, MER11, RAD50, NBS1, ATR; amplification of EMSY); or germline mutation in BRCA1 or BRCA 2 (not breast or ovarian cancer)
- Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- Absolute neutrophil count >= 1500/mL
- Platelets >= 100,000/mL
- Hemoglobin >= 9 g/dL (or >= 5.6 mmol/L)
- Serum creatinine =< 1.5 x upper limit of normal (ULN) (or glomerular filtration rate [GFR] >= 60 ml/min for patients with creatinine > 1.5 x ULN)
- Serum total bilirubin =< 1.5 x ULN (direct bilirubin =< ULN if total bilirubin [bili] > 1.5 x ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (or =< 5 x ULN if liver metastases [mets])
- International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants; activated PTT (aPTT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- Patients must be >= 4 weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents; or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation
- Women of child-bearing potential MUST have a negative serum or urine human chorionic gonadotropin (HCG) test unless prior tubal ligation (>= 1 year before screening), total hysterectomy or menopause (defined as 12 consecutive months of amenorrhea); patients should not become pregnant or breastfeed while on this study; sexually active patients must agree to use dual contraception for the duration of study participation and for 120 days after the last dose of talazoparib
- Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures
- Patients need to have biopsiable disease to enroll on cohort 1-2; patients eligible for cohort 3 with a germline BRCA alteration can be enrolled even if they do not have biopsiable disease
Exclusion Criteria:
- Patients who are pregnant or breastfeeding
- Prior treatment with a PARP inhibitor
- Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
- Inability or unwillingness to swallow pills
- Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization
- Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)
- Inability to comply with the study and follow-up procedures
- History of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous 6 months before starting therapy
- Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
- Has a known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless or clinical stability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (talazoparib)
Patients receive talazoparib PO QD on days 1-28.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit by Response Evaluation Criteria in Solid Tumors 1.1
Time Frame: Up to 1 year
|
Evaluated separately in each cohort.
Calculated using posterior probabilities along with corresponding credible intervals.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: Up to 1 year
|
Calculated using the Kaplan-Meier method.
|
Up to 1 year
|
Overall survival
Time Frame: Up to 1 year
|
Calculated using the Kaplan-Meier method.
|
Up to 1 year
|
Duration of response
Time Frame: Up to 1 year
|
Calculated using the Kaplan-Meier method.
|
Up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecular markers that may predict clinical benefit
Time Frame: Baseline
|
Marker values will be compared between patients with and without clinical benefit using chi-squared or Fisher exact tests for categorically-scaled markers and Wilcoxon rank sum tests for interval- and ordinal-scaled markers.
Only those significant on univariate analysis will be combined into a single logistic regression model to assess their independent effects on clinical benefit.
Analyses will be performed both within and across the five cohorts.
|
Baseline
|
Pharmacodynamic markers in blood and plasma that may predict outcome
Time Frame: Up to week 4
|
Regulation of poly-adenosine triphosphate ribose activity in peripheral blood mononuclear cells will be correlated with response.
Effect of treatment on proteomic profile and cell-free deoxyribonucleic acid will be assessed as exploratory endpoints.
|
Up to week 4
|
BRCA1/2 alterations in archival tissue
Time Frame: Baseline
|
Concordance between archival tissue and pre-treatment biopsies will be assessed using kappa statistics.
|
Baseline
|
BRCA1/2 alterations in pretreatment biopsies
Time Frame: Baseline
|
Concordance between archival tissue and pre-treatment biopsies will be assessed using kappa statistics.
|
Baseline
|
Genomic alterations in tumor deoxyribonucleic acid
Time Frame: Baseline
|
Concordance between tumor and circulating free deoxyribonucleic acid will be assessed using kappa statistics.
|
Baseline
|
Genomic alterations in circulating free deoxyribonucleic acid
Time Frame: Up to week 4
|
Concordance between tumor and circulating free deoxyribonucleic acid will be assessed using kappa statistics.
|
Up to week 4
|
Change in marker levels
Time Frame: Baseline to 2 weeks
|
The markers described yield interval-scaled values that may not be normally distributed, so differences between baseline and 2-week values will be assessed using the Wilcoxon signed-rank test.
|
Baseline to 2 weeks
|
Baseline proteomic signature and pharmacodynamic response by reverse phase protein array
Time Frame: Baseline
|
Pharmacodynamic effect of talazoparib on proteomic signature will be assessed by reverse phase protein array and correlated with response, clinical benefit, as well as best response as percentage tumor change.
|
Baseline
|
Archival immunohistochemistry staining
Time Frame: Baseline
|
Immunohistochemistry staining will be assessed via the H-score which can be treated as an interval-scaled variable.
The concordance correlation coefficient as well as the Altman-Bland approach will be used to assess the concordance between archival immunohistochemistry staining and baseline biopsy immunohistochemistry staining.
In addition, PTEN will be assessed (PTEN loss, no loss).
Concordance between archival tissue and pre-treatment biopsies will be assessed using kappa statistics.
|
Baseline
|
Baseline biopsy immunohistochemistry staining
Time Frame: Baseline
|
Immunohistochemistry staining will be assessed via the H-score which can be treated as an interval-scaled variable.
The concordance correlation coefficient as well as the Altman-Bland approach will be used to assess the concordance between archival immunohistochemistry staining and baseline biopsy immunohistochemistry staining.
In addition, PTEN will be assessed (PTEN loss, no loss).
Concordance between archival tissue and pre-treatment biopsies will be assessed using kappa statistics.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarina A Piha-Paul, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-0961 (Other Identifier: M D Anderson Cancer Center)
- NCI-2014-02494 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BRCA1 Gene Mutation
-
Rabin Medical CenterUnknownBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
Ohio State University Comprehensive Cancer CenterRecruitingBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
University of California, San FranciscoAmerican Cancer Society, Inc.CompletedBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
Pamela MunsterNational Cancer Institute (NCI)RecruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
University of California, San FranciscoGlaxoSmithKlineRecruitingMetastatic Solid Tumor | BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene MutationUnited States
-
Rabin Medical CenterCompletedBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
University Medical Center NijmegenRecruitingOvarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene MutationNetherlands, United States, Belgium, Norway, Poland, Italy, Australia, Mexico, Brazil, Sweden, Uruguay
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditionsUnited States
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Beth Israel Deaconess Medical CenterJohns Hopkins University; Dana-Farber Cancer Institute; AstraZenecaActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)United States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed